Revolution Medicines (RVMD) - Utang jangka dawa marang modal

Lambang korporat lan logo Revolution Medicines (RVMD)

Due to the humanitarian status of drug development, Revolution Medicines (RVMD) maintains stable operations regardless of geopolitics. The company's revenues are based on bringing innovative drugs to market for the treatment of gastrointestinal and lung tumors. The market trend demonstrates the 0.47 indicator, while financial success relies on the demand from government funds and clinics for unique therapy methods for complex mutations.

RevMed - Utang jangka dawa marang modal RVMD (periode 04.07.2022 - 31.10.2026)
Produk asli revmed.com

This ratio determines the degree of financial leverage by comparing the total amount of liabilities with a maturity of more than one year to total equity. By analyzing the long-term debt-to-equity ratio, an investor assesses the stability of the financing structure of Revolution Medicines (RVMD), where the balance of borrowed funds is critical for sustaining the costly development of innovative RAS inhibitors and strengthening the company's therapeutic advantage.

Pesaing wigati

Rasio utang jangka dawa marang ekuitas BeiGene Ltd. (ONC)|Utang jangka dawa marang modal HALO|Utang jangka dawa marang modal Ascentage Pharma Corp (AAPG)|Utang jangka dawa marang ekuitas CG Oncology, Inc. CGON|URGN: Rasio utang jangka dawa marang modal|Bicara Therapeutics - Utang jangka dawa marang modal|Personalis Inc (PSNL) - Rasio utang jangka dawa marang ekuitas|ERAS: Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Delcath Corp (DCTH)|Utang jangka dawa marang ekuitas Y-mAbs Therapeutics|AURA: Koefisien utang jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas CADL (Candel Therapeutics)|ARAY (Accuray Inc) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal SLS (SELLAS Life Sciences Group)|ACTU - Rasio utang jangka dawa marang ekuitas|CTOR: Rasio utang jangka dawa marang ekuitas|HURA - Utang jangka dawa marang modal|Protara Therapeutics, Inc. (TARA) - Utang jangka dawa marang ekuitas|Fate Therapeutics Inc - Koefisien utang jangka dawa marang modal|WHWK (Aadi Bioscience, Inc.) - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal TScan TCRX|Utang jangka dawa marang ekuitas Champions Oncology (CSBR)|XBIT (xbiotech.com) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang modal CVM (CEL-SCI)|OS Therapies Inc. (OSTX) - Kewajiban jangka dawa marang modal|RADX: Rasio utang jangka dawa marang ekuitas|ARTV: Utang jangka dawa marang ekuitas|adlainortye.com (ANL) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal verupharma.com (VERU)|Utang jangka dawa marang ekuitas Tempest Therapeutics, Inc.|Utang jangka dawa marang ekuitas XLO|Rasio utang jangka dawa marang ekuitas RENB (Renovaro Inc.)|Utang jangka dawa marang modal muraloncology.com (MURA)|Kairos Pharma - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka dawa marang modal OKUR (OnKure Therapeutics, Inc.)|CytoMed - Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal Curis, Inc. CRIS|apollomicsinc.com (APLM) - Utang jangka dawa marang ekuitas|Kewajiban jangka dawa marang modal Tharimmune Corporation (THAR)|Utang jangka dawa marang ekuitas Advanced Biomed Inc.|Rasio utang jangka dawa marang modal GNPX (genprex.com)|Rasio utang jangka dawa marang ekuitas CLDI (Calidi Biotherapeutics)|SBFM (Sunshine Biopharma Inc.) - Koefisien utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Xenetic Biosciences, Inc. XBIO|SLRX - Rasio utang jangka dawa marang ekuitas|Purple Biotech - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal American Oncology Network|BGNE: Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal CKPT|ELEV (Elevation Oncology, Inc.) - Utang jangka dawa marang modal|iCAD Corp (ICAD) - Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang modal IKNA|Rasio utang jangka dawa marang ekuitas notablelabs.com NTBL|Utang jangka dawa marang modal VIRX (Viracta Therapeutics, Inc.)|Rasio tanggungan utang jangka dawa marang modal MorphoSys Inc (MOR)|NAYA - Utang jangka dawa marang ekuitas|AAPGV (Ascentage) - Rasio utang jangka dawa marang modal